NICE Rebuffs Reimbursement of Takeda’s Hodgkin’s Lymphoma Drug Adcetris

The UK’s National Institute for Health and Care Excellence has recommended against reimbursing Takeda’s Hodgkin's lymphoma drug Adcetris.

In August, the UK price watchdog rejected reimbursement, because of the immature and limited data on drug’s efficacy.

Takeda submitted new data and analyses to NICE, but the agency determined that, even with the new findings, there was uncertainty surrounding the clinical evidence and Adcetris could not be rendered as cost effective.